Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fasting Conditions.
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2010-10-14
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01089192
- Locations
- 🇮🇳
Torrent Research Centre, Bhat, Gujarat, India
Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet in Healthy Volunteers Under Fed Conditions.
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2010-07-29
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01089205
Bioequivalence Study of Metformin Hydrochloride Extended Release 500 mg Tablet Versus Glucophage XR® 500 mg Tablet in Healthy Volunteers Under Fed Conditions
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2010-05-07
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01089179
- Locations
- 🇮🇳
Torrent Research Centre, Bhat, Gujarat, India
Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01089166
- Locations
- 🇮🇳
Torrent Research Centre, Bhat, Gujarat, India
Metformin Versus Insulin in the Treatment of Gestational Diabetes Mellitus
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2010-03-16
- Lead Sponsor
- University of Oulu
- Target Recruit Count
- 97
- Registration Number
- NCT01087866
- Locations
- 🇫🇮
Oulu University Hospital, Oulu, Finland
Lapatinib With Sirolimus or Metformin
- Conditions
- Advanced Cancers
- Interventions
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT01087983
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2010-03-10
- Lead Sponsor
- Wolfson Medical Center
- Registration Number
- NCT01084486
- Locations
- 🇮🇱
Wolfson Medical Center, Holon, Israel
Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Western Sydney Local Health District
- Target Recruit Count
- 28
- Registration Number
- NCT01077479
- Locations
- 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 427
- Registration Number
- NCT01076075
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 810
- Registration Number
- NCT01075282
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yung-Kang, Tainan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.